Key result
Methoxy polyethylene glycol epoetin beta boosts hemoglobin ~22%, improving LVEF in heart failure with anemia.
Why the study?
Anemia is common in chronic heart failure and is an independent predictor of mortality, but its treatment remains undefined due to unclear pathogenesis and conflicting study results with erythropoiesis-stimulating agents and iron therapies.
RCT (n=84)
Randomized into two groups
No
Aim. To study erythropoietic activity and safety of methoxy polyethylene glycol epoetin beta (MEB) and its effects on haemoglobin (Hb), erythropoietin, ferritin, NT-proBNP, cytokines, and chronic heart failure (CHF) symptoms and signs. Material and methods . In total, 84 patients with Functional Class (FC) II–IV (NYHA) CHF and anaemia were examined (mean age 59,7±1,6 years; 54 men and 30 women). Anaemia criteria were Hb levels <120 g/l in men and <110 g/l in women. CHF was due to coronary heart disease, CHD (post-infarction cardiosclerosis; n=40); to CHD in combination with Type 2 diabetes mellitus, DM-2 (n=10), and arterial hypertension, AH (n=14); and to the combination of CHD, AH, and DM-2 (n=10). Left ventricular ejection fraction (LVEF) in CHF patients with FC II, III, and IV was
No takes yet. Share an insight, caveat, or question.
Zakhidova et al. (2013) conducted an RCT in Chronic heart failure with anemia (n=84). Methoxy polyethylene glycol epoetin beta (MEB) vs. Standard therapy was evaluated on Hemoglobin level at 6 months (21.9% increase from baseline, p=<0.05). Methoxy polyethylene glycol epoetin beta significantly increased hemoglobin levels by 21.9% and improved left ventricular ejection fraction and exercise capacity in patients with chronic heart failure and anemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: